Jul 06, 2018 / 12:35
Japan's Taisho Group offers to buy extra 7.06% stake in DHG Pharmaceutical
The deal is expected to cost the Japanese pharmaceutical company VND1.1 trillion (US$47.68 million).
Japan-based Taisho Group has announced its intention to purchase another 7.06% stake of DHG Pharmaceutical JSC (DHG) in a public offer at a price of VND120,000 (US$5.20) apiece, 20% higher than the market price of VND99,900 (US$4.34) at the close on July 4, DHG said in a filing to the Ho Chi Minh City Stock Exchange (HOSE).
At such price, Taisho Group is expected to spend nearly VND1.1 trillion (US$47.68 million) in exchange for 9.2 million shares of Hau Giang Pharmaceutical.
Once the deal is completed, Taisho Group will increase its holding in the Vietnamese firm to 32% or over 41.83 million shares. The proposed time to realize this public offer is within 30 to 60 days after receiving the written approval from the State Securities Commission of Vietnam (SSC) on the public offer.
The Japanese group in early June spent VND85.5 billion (US$3.71 million) for 650,000 shares of DHG, raising its holding in the Vietnamese medicine producer to 24.94%.
Over the past month, DHG shares have lost 13% in value. However, since its listing, the company's share value increased a whooping of 459% to VND99,900 (US$4.34) per share at the close on July 4.
The shares then increased by 5.31% to VND105,200 (US$4.57) apiece at the close of July 5.
On July 4, DHG Pharmaceutical's foreign ownership limit was removed, as a result, the company adjusted its strategic targets for period 2018 - 2020 to a minimum increase of revenue at 13% and pre-tax profit of at least 7%.
Illustration photo.
|
Once the deal is completed, Taisho Group will increase its holding in the Vietnamese firm to 32% or over 41.83 million shares. The proposed time to realize this public offer is within 30 to 60 days after receiving the written approval from the State Securities Commission of Vietnam (SSC) on the public offer.
The Japanese group in early June spent VND85.5 billion (US$3.71 million) for 650,000 shares of DHG, raising its holding in the Vietnamese medicine producer to 24.94%.
Over the past month, DHG shares have lost 13% in value. However, since its listing, the company's share value increased a whooping of 459% to VND99,900 (US$4.34) per share at the close on July 4.
The shares then increased by 5.31% to VND105,200 (US$4.57) apiece at the close of July 5.
On July 4, DHG Pharmaceutical's foreign ownership limit was removed, as a result, the company adjusted its strategic targets for period 2018 - 2020 to a minimum increase of revenue at 13% and pre-tax profit of at least 7%.
Other News
- Better links with FDI firms to support Hanoi businesses
- Vietnam calls for more US investment in innovation, hi-tech
- Vietnamese leader urges Boeing to build production facility in Vietnam
- Foreign capital pouring into Vietnam's real estate market
- Vietnam news in brief - August 24
- Growing number of FDI firms moving to Vietnam
- Vietnam Gov’t committed to facilitating Adani Group’s US$2-billion port project
- Vietnam Railway proposes US$87 million for Hanoi–Dong Dang railway upgrade
- Vietnam’s North-South high-speed railway to be designed for 350km/h
- Vietnamese gov’t urged to address impact of global minimum tax
Trending
-
Vietnam contributes US$10 million to Mekong sub-region development fund
-
Vietnam news in brief - November 8
-
Hanoi to strengthen ties with Argentina's localities via cultural programs
-
From tradition to trend: How modern approaches spark cultural pride in Vietnam's Gen Z
-
Hanoi works to make bus system greener
-
Capital Law to make Hanoi major center for quality education
-
Expatriate workforce in Hanoi: Growth engine requring thorough administration
-
Hanoi seeks partnerships to build skilled workforce for digital transformation
-
Adorable baby hippo wows Hanoi visitors